Secukinumab

Secukinumab is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis.


Cat. No.: EX-A6993	Purity: >98%

	Chemical structure of Secukinumab

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
10mg	550	In-stock
25mg	get quote	In-stock
50mg	get quote	In-stock
100mg	get quote	In-stock
200mg	get quote	In-stock
500mg	get quote	In-stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


Synonyms	AIN457
CAS No.	1229022-83-6
Purity	>98%
Color	colorless to light yellow (sol
State	liquid
Storage	Store at 4℃, Do not freeze
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Shirley M, et al. Secukinumab: A Review in Psoriatic Arthritis. Drugs. 2016;76(11):1135-1145. [2]. Reich K, et al. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. Br J Dermatol. 2020;182(2):304-315. [3]. Elain G, et al. The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes. Glia. 2014;62(5):725-735.
CoA	CoA of Secukinumab


		Search